2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Molecular Testing, Omics Technologies, Bioinformatics, Computational Biology, Emerging Technologies, Treatment Considerations, Biological Therapies, Immunotherapy, Non-Biological Therapies, Chemotherapy, Biological Processes, CHIP, Genomics, Hematopoiesis, Immune Mechanism, Molecular Biology, Diseases, Bone Marrow Failure Syndromes, Inherited Marrow Failure Syndromes, Genetic Disorders, Immunology, Autoimmune Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Research, Fundamental Science, AML, Translational Research, MDS, MPN, CMML, Clinical Research, Study Population, Human, Adult, Elderly, Pediatric, Young Adult
PAPER

5585 Luspatercept in lower-risk myelodysplastic syndrome: A pilot clinical trial with single-cell transcriptomic analysis

Alex Bataller, MD, PhD, Yue Wei, PhD2, Guillermo Montalban-Bravo, MD3, Kelly Sharon Chien, MD4, Ian Bouligny, M.D.5, Alexandre Bazinet, MD, MSc6, Danielle Hammond, MD7, Francesco Pesce, MD8, Vera Adema, PhD9, Simona Colla, PhD10, Xiaoping Su, PhD11, Sanam Loghavi, MD12, Hui Yang, MD, PhD13, Guillermo Garcia-Manero, MD14
1 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
2 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
3 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
4 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
5 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
6 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
7 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
8 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
9 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
10 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
11 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
12 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
13 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
14 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Background: Luspatercept, is a TGFβ ligand trap (GDF-8, GDF-11, activin B), approved for the treatment of lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. Although, the mechanism by which Luspatercept restores early erythropoiesis remains unclear, GDF11-induced GATA1 alternative splicing has recently been proposed as a key driver. The effects of Luspatercept on distinct bone marrow (BM) cell types remain unknown. Here, we report the results from a phase 2 clinical trial in LR-MDS patients treated with Luspatercept, focusing on transcriptomic alterations at single-cell resolution following drug exposure.

Methods: This is a pilot, open-label clinical trial (NCT06113302) that enrolled 10 patients with transfusion dependent (TD, ³2 transfusions in previous 8 weeks, n=2) or independent (TI, n=8) LR-MDS. Patients received luspatercept following current US FDA guidelines. The primary objectives were to assess clinical activity and study the effects of luspatercept in hematopoiesis. Bone marrow (BM) samples at baseline and response assessment were processed for single cell RNA sequencing (scRNAseq).

Results: The median age was 65 years (range, 41-82), and 50% were male. At treatment initiation, the median hemoglobin (hgb) was 96 g/L (range, 82-116), the median platelet count was 53 x10⁹/L (range, 31-303), and the median absolute neutrophil count (ANC) was 0.92 x10⁹/L (range, 0.62-5.2). BM ring sideroblasts were >15% in 2 patients. Four patients had a normal karyotype, 2 had deletion 20q, 2 had trisomy 8 (one with an additional deletion 20q), 1 had deletion 5q, and the remaining patient had deletion 16q. Molecular testing revealed U2AF1 mutations in 3 patients (one with a co-occurring RUNX1 mutation) and SF3B1 (p.K700E) in 2 patients (combined with ZRSR2 in one and with ASXL1and SETBP1 in the other). One patient had multiple mutations (ASXL1, RUNX1, SRSF2, STAG2, and TET2), one had a TP53 mutation (6% allelic fraction), and one had a TET2 mutation; the remaining 2 patients had no detectable mutations by NGS.

Five patients achieved erythroid response (>15 g/L hgb increase from baseline, classified as responders) after treatment initiation. Among patients with baseline platelets <100 × 10⁹/L, none achieved platelet response (>30 x10⁹/L increase from baseline). Among patients with baseline ANC <1 x10⁹/L, one achieved a significant ANC response (>100% increase from baseline).

scRNA-seq analysis of bone marrow cell proportions revealed an expansion of the CFU-E proportion from baseline to response (16% to 29% of all erythroid cells) and a contraction of late erythroid populations (84% to 71%), driven mostly by reductions in polychromatophilic erythroblasts (20% to 11%) and orthochromatic erythroblasts (26% to 18%), among other subtypes. In non-responders, the CFU-E proportion decreased from baseline to non-response (25% to 15%), with expansion of late erythroid populations, notably polychromatic erythroblasts (18% to 38%), orthochromatic erythroblasts (3% to 10%), and pre-erythrocytes (6% to 15%). In both early and late erythroid populations, post-treatment samples showed enrichment of the heme metabolism pathway. However, responders additionally showed positive enrichment for pathways involved in cell-cycle progression (G2M checkpoint, mitotic spindle, E2F targets in CFU-E), proliferation (MYC targets V1, both in CFU-E and late erythroid populations), and mitochondrial activity (oxidative phosphorylation in late erythroid populations), whereas non-responders showed negative enrichment for these same pathways. In responders, key genes involved in erythroid regulation (GATA1, KLF1, EPOR, among others) were upregulated in late erythroid precursors at response compared to baseline.

At baseline, CD4+ T cells showed upregulation of the TGF-β signaling pathway in responders compared to non-responders. After treatment, TGF-β signaling was downregulated across monocytes, B cells, and CD4+/CD8+ T cells in both responders and non-responders compared to baseline. Analyses are ongoing to better understand differences in inflammatory pathways between responders and non-responders.

Conclusion: Luspatercept induces significant transcriptional changes in erythroid precursors, marked by CFU-E expansion and upregulation of pathways involved in red blood cell and heme production. Non-erythroid lineages also show differential pathway enrichment, though the biological significance of these changes remains unclear.

Alex Bataller, MD, PhD: No relevant conflicts of interest to declare.